LOPERAMIDE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Loperamide Hydrochloride patents expire, and what generic alternatives are available?
Loperamide Hydrochloride is a drug marketed by Aurobindo Pharma Ltd, Bionpharma, Chartwell Rx, Edenbridge Pharms, Jubilant Cadista, Mylan, Roxane, Rubicon, Strides Pharma, Teva, Zydus Lifesciences, Allied, Alpharma Us Pharms, Duramed Pharms Barr, Perrigo, Saptalis Pharms, Watson Labs, Wockhardt Bio Ag, Perrigo R And D, Able, Aurobindo Pharma, Contract Pharmacal, L Perrigo Co, LNK, Ohm Labs, Granules, Guardian Drug, Hetero Labs Ltd V, and Sun Pharm Inds Ltd. and is included in thirty-seven NDAs.
The generic ingredient in LOPERAMIDE HYDROCHLORIDE is loperamide hydrochloride; simethicone. There are eleven drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the loperamide hydrochloride; simethicone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Loperamide Hydrochloride
A generic version of LOPERAMIDE HYDROCHLORIDE was approved as loperamide hydrochloride; simethicone by SUN PHARM INDS LTD on September 6th, 2006.
Summary for LOPERAMIDE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 29 |
NDAs: | 37 |
Finished Product Suppliers / Packagers: | 98 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Clinical Trials: | 76 |
Patent Applications: | 3,264 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LOPERAMIDE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for LOPERAMIDE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Infectious Diseases Clinical Research Program | Phase 4 |
Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase 4 |
Uniformed Services University of the Health Sciences | Phase 4 |
Pharmacology for LOPERAMIDE HYDROCHLORIDE
Drug Class | Opioid Agonist |
Mechanism of Action | Opioid Agonists |